CTLA4 and metastatic melanoma: To date, ICIs such as the CTLA-4 inhibitor (ipilimumab), the PD-1 inhibitor (nivolumab and pembrolizumab) have been approved by the U.S. Food and Drug Administration for the treatment of metastatic melanoma and have demonstrated significant efficacy (10–12).